752 Shares in Stryker Co. (NYSE:SYK) Purchased by Oak Thistle LLC

Oak Thistle LLC purchased a new position in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 752 shares of the medical technology company's stock, valued at approximately $271,000.

Several other hedge funds have also recently made changes to their positions in the company. Dunhill Financial LLC raised its position in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 37 shares in the last quarter. Centennial Bank AR grew its stake in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company's stock worth $32,000 after purchasing an additional 48 shares during the period. Darwin Wealth Management LLC purchased a new position in shares of Stryker during the 3rd quarter valued at approximately $36,000. Hara Capital LLC purchased a new stake in Stryker during the third quarter worth $42,000. Finally, HBW Advisory Services LLC acquired a new stake in Stryker during the third quarter valued at $42,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of several recent analyst reports. StockNews.com raised shares of Stryker from a "hold" rating to a "buy" rating in a research note on Thursday, January 9th. Royal Bank of Canada reiterated an "outperform" rating and set a $425.00 price target on shares of Stryker in a research report on Tuesday, January 7th. JPMorgan Chase & Co. boosted their price objective on Stryker from $375.00 to $420.00 and gave the company an "overweight" rating in a research report on Wednesday, October 30th. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a research note on Tuesday, January 7th. Finally, UBS Group upped their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $405.80.

Stryker Stock Up 0.6 %

Shares of SYK traded up $2.12 during mid-day trading on Friday, reaching $383.91. The company's stock had a trading volume of 1,727,106 shares, compared to its average volume of 1,070,245. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a 12-month low of $307.23 and a 12-month high of $398.20. The stock has a market cap of $146.35 billion, a PE ratio of 41.15, a price-to-earnings-growth ratio of 2.51 and a beta of 0.95. The company's 50 day moving average is $375.51 and its 200 day moving average is $358.81.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm's revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.46 earnings per share. Equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. This is a boost from Stryker's previous quarterly dividend of $0.80. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker's payout ratio is presently 36.01%.

Insider Activity at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.